Progress and challenges towards targeted delivery of cancer therapeutics

By Daniel Rosenblum, N. Joshi, Wei Tao, J. Karp, D. Peer. Nature Communications, 2018

1,807 citations recorded by the source corpus.

Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials. Herein, we review the principles behind targeted delivery approaches to determine potential reasons for their limited clinical translation and success. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs. We also highlight the possible directions for the development of successful tumor targeting strategies.Targeted delivery strategies based on nanocarriers have immense potential to change cancer care but current strategies have been shown only limited translation in the clinic. Here, the authors survey the challenge, progress and opportunities towards targeted delivery of cancer therapeutics.

Subfields: Biomaterials, Biomedical Engineering, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/f6531b41fcff43673d310d344527fc57209421b5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Julio César Díaz Vera
2. Xin Lai
3. Yujie You
4. Le Zhang
5. Suran Liu
6. Ying Pan
7. Huiru Zheng
8. Senyi Deng

Citations in the corpus

• Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. (2019, neutral): “greatest challenges in nanomedicine research [4].”
• Nanomedicine in cancer therapy (2023, background): “28 29 – 31 Moving beyond the fi rst-generation cancer nanomedicines which aim to increase the accumulation of nanotherapeutics within solid tumors and thus to reduce off-target effects via tissue-speci fi c targeting, the second-generation cancer nanomedicines further strive for selective and…”
• Artificial intelligence in cancer target identification and drug discovery (2022, background): “As a result, these therapies could have undesired impacts on normal tissues and even provoke serious side effects for patients 7,8 .”